Extrawell Pharmaceutical Holdings First Half 2025 Earnings: EPS: HK$0.042 (vs HK$0.099 loss in 1H 2024)

Extrawell Pharmaceutical Holdings (HKG:858) First Half 2025 Results

Key Financial Results

• Net income: HK$100.9m (up from HK$237.7m loss in 1H 2024).
• EPS: HK$0.042 (up from HK$0.099 loss in 1H 2024).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Extrawell Pharmaceutical Holdings shares are up 2.1% from a week ago.

Risk Analysis

Be aware that Extrawell Pharmaceutical Holdings is showing 4 warning signs in our investment analysis and 2 of those make us uncomfortable...

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.